Black Diamond Therapeutics

General Information


We are a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. We target undrugged oncogenic driver mutations in patients with genetically-defined cancers. The foundation of our company is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. Our proprietary technology platform, which we refer to as our Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow us to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types.

Employees: 31
Founded: 2014
Contact Information
Address 139 Main Street, Cambridge, MA 02142, US
Phone Number 617-252-0848
Web Address
View Prospectus: Black Diamond Therapeutics
Financial Information
Market Cap $554.8mil
Revenues $0 mil (last 12 months)
Net Income $-28.4 mil (last 12 months)
IPO Profile
Symbol BDTX
Exchange NASDAQ
Shares (millions): 10.6
Price range $19.00 - $19.00
Est. $ Volume $201.2 mil
Manager / Joint Managers J.P. Morgan/ Jefferies/ Cowen and Company
CO-Managers Canaccord Genuity
Expected To Trade: 1/30/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change